Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4822 participants.
Also called NCT01920711
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,822 participants
- Sponsor
- Registry
-
NCT01920711 -
2013-001747-31
-
- Other papers using this trial's data
- Analysis of the PARAGON-HF Study Results Using Win Ratio
- Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF Trial
- Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction
- Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF
- Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
- Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF
- Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
- Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction
- Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
- Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial
- Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF
- Prognostic Significance of Nutritional Scores in Patients With Heart Failure: Insights From the PARAGON-HF Trial
- Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial
- Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
- Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
- Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction
- Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON-HF trial
- Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Guatemala, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Romania, Russia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01920711. Randomized; double masking; primary purpose treatment. Start 2014-07-18 (actual); primary completion 2019-06-07 (actual). Results posted on 2020-09-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
- Acronym
- PARAGON-HF
- Intervention (Drug)
- LCZ696
- Intervention (Drug)
- Valsartan
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01920711- Content hash
072d0d61d0ef63eb7943fba67129998d1b563cbc0c53ce2f4ce2b4c2ee8298ec